CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Shanghai Fosun Pharmaceutical (Group) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Shanghai Fosun Pharmaceutical (Group)
Cao Yang Lu 510Hao 9Lou
Phone: +86 2133987870p:+86 2133987870 SHANGHAI, SHA  100000  China Ticker: 600196600196
Business Summary
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a China-based company principally engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company operates its businesses through five segments. The Pharmaceuticals segment is primarily engaged in the research, development, production and sales of pharmaceuticals. The Medical Devices and Diagnostics segment is primarily engaged in the research, development, production and sales of medical devices and diagnostic products. The Healthcare Services segment is primarily engaged in the provision of healthcare services and hospital management. The Pharmaceutical Distribution and Retail segment primarily engages in the distribution and retail of pharmaceuticals and medical devices. The Company also operates the Other segment. The Company mainly operates its businesses in the domestic market and overseas markets.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
3841 Surgical and medical instruments and apparatus
2835 In vitro and in vivo diagnostic substances
8099 Health and allied services, not elsewhere classified
3845 Electromedical and electrotherapeutic apparatus
8062 General medical and surgical hospitals
5122 Drugs, drug proprietaries, and druggists' sundries
5912 Drug stores and proprietary stores
3843 Dental equipment and supplies
8999 Services, not elsewhere classified
6099 Functions related to depository banking, not elsewhere classified
7389 Business services, not elsewhere classified
7312 Outdoor advertising services
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board YuqingChen 50 6/24/2025 4/1/2015
Executive Co-Chairman of the Board XiaohuiGuan 55 4/29/2025 6/8/2016
President, Chief Executive Officer, Executive Director YiLiu 50 12/2/2025 1/15/2017
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Gland Pharma Ltd Survey No.143-148,150&151 HYDERABAD India
Breas Medical AB Foretagsvogen 1 Molnlycke Sweden
Breas Medical Holdings AB Fretagsvgen 1 Molnlycke Sweden
3 additional Subsidiary records available in full report.

Business Names
Business Name
2196
600196
Breas Medical AB
7 additional Business Names available in full report.

General Information
Number of Employees: 40,603 (As of 12/31/2025)
Outstanding Shares: 2,670,429,325 (As of 3/31/2026)
Shareholders: 219,651
Stock Exchange: SHA
Fax Number: +86 2133987871


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 13, 2026